WuXi Biologics (Cayman) Inc logo

2269 - WuXi Biologics (Cayman) Inc Share Price

HK$218.6 -4.6  -2.1%

Last Trade - 23/10/20

Sector
Healthcare
Size
Large Cap
Market Cap £29.34bn
Enterprise Value £29.16bn
Revenue £494.3m
Position in Universe 32nd / 6000
Bullish
Bearish
Unlock 2269 Revenue
Momentum
Relative Strength (%)
1m +10.2%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -6.18%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
126.8
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
331.9 557 989 1,619 2,534 3,984 5,368 7,747 +64.4%
+6.2 +274 +33.0 +124.8 +47.3 +51.6 +35.2
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, WuXi Biologics (Cayman) Inc revenues increased 21% to RMB1.94B. Net income increased 64% to RMB736.1M. Revenues reflect Revenue on fee-for-service basis segment increase of 22% to RMB1.83B, Revenue on full-time-equivalent basis segment increase of 34% to RMB59.3M, People's Republic of China segment increase of 43% to RMB815.7M, Rest of the World segment increase of 62% to RMB127.5M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for 2269
Graphical History

Revenue

2269 Revenue Unlock 2269 Revenue

Net Income

2269 Net Income Unlock 2269 Revenue

Normalised EPS

2269 Normalised EPS Unlock 2269 Revenue

PE Ratio Range

2269 PE Ratio Range Unlock 2269 Revenue

Dividend Yield Range

2269 Dividend Yield Range Unlock 2269 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
2269 EPS Forecasts Unlock 2269 Revenue
Profile Summary

WUXI BIOLOGICS (CAYMAN) INC. is an investment holding company. The Company along with its subsidiaries is mainly engaged in the discovery, research and development, manufacturing and sales of biologics products. The Company’s primary products include the clinical active pharmaceutical ingredients, sterile liquid preparations, freeze-dried preparations, as well as small molecules antibiotics for injection drugs. The Company mainly distributes its products in the United States of America (USA) and the People’s Republic of China (PRC) markets.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated February 27, 2014
Public Since June 13, 2017
No. of Shareholders: n/a
No. of Employees: 5,694
Sector Healthcare
Industry Pharmaceuticals
Index Hang Seng Composite , Hang Seng , Hang Seng Composite LargeCap & MidCap ,
Exchange Stock Exchange of Hong Kong Limited
Shares in Issue 1,360,528,974
Free Float (0.0%)
Eligible for
ISAs
SIPPs
2269 Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for 2269
Upcoming Events for 2269
Monday 16th November, 2020
WuXi Biologics (Cayman) Inc Split For 2269.HK - Ratio 3-1
Frequently Asked Questions for WuXi Biologics (Cayman) Inc
What is the WuXi Biologics (Cayman) Inc share price?

As of 23/10/20, shares in WuXi Biologics (Cayman) Inc are trading at HK$218.6, giving the company a market capitalisation of £29.34bn. This share price information is delayed by 15 minutes.

How has the WuXi Biologics (Cayman) Inc share price performed this year?

Shares in WuXi Biologics (Cayman) Inc are currently trading at HK$218.6 and the price has moved by 0.173k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the WuXi Biologics (Cayman) Inc price has moved by 0.171k% over the past year.

What are the analyst and broker recommendations for WuXi Biologics (Cayman) Inc?

Of the analysts with advisory recommendations for WuXi Biologics (Cayman) Inc, there are there are currently 10 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for WuXi Biologics (Cayman) Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will WuXi Biologics (Cayman) Inc next release its financial results?

WuXi Biologics (Cayman) Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the WuXi Biologics (Cayman) Inc dividend yield?

WuXi Biologics (Cayman) Inc does not currently pay a dividend.

Does WuXi Biologics (Cayman) Inc pay a dividend?

WuXi Biologics (Cayman) Inc does not currently pay a dividend.

When does WuXi Biologics (Cayman) Inc next pay dividends?

WuXi Biologics (Cayman) Inc does not currently pay a dividend.

How do I buy WuXi Biologics (Cayman) Inc shares?

To buy shares in WuXi Biologics (Cayman) Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of WuXi Biologics (Cayman) Inc?

Shares in WuXi Biologics (Cayman) Inc are currently trading at HK$218.6, giving the company a market capitalisation of £29.34bn.

Where are WuXi Biologics (Cayman) Inc shares listed? Where are WuXi Biologics (Cayman) Inc shares listed?

Here are the trading details for WuXi Biologics (Cayman) Inc:

Country of listing: Hong Kong
Exchange: HKG
Ticker Symbol: 2269
What kind of share is WuXi Biologics (Cayman) Inc?

Based on an overall assessment of its quality, value and momentum, WuXi Biologics (Cayman) Inc is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a WuXi Biologics (Cayman) Inc share price forecast 2020?

Shares in WuXi Biologics (Cayman) Inc are currently priced at HK$218.6. At that level they are trading at 17.77% premium to the analyst consensus target price of 0.00.

Analysts covering WuXi Biologics (Cayman) Inc currently have a consensus Earnings Per Share (EPS) forecast of 1.1550282307 for the next financial year.

How can I tell whether the WuXi Biologics (Cayman) Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like WuXi Biologics (Cayman) Inc. Over the past six months, the relative strength of its shares against the market has been 54.69%. At the current price of HK$218.6, shares in WuXi Biologics (Cayman) Inc are trading at 55.87% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the WuXi Biologics (Cayman) Inc PE Ratio?

The WuXi Biologics (Cayman) Inc PE ratio based on its reported earnings over the past 12 months is 0.191k. The shares are currently trading at HK$218.6.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of WuXi Biologics (Cayman) Inc?

WuXi Biologics (Cayman) Inc's management team is headed by:

Zhisheng Chen - CEO
Weichang Zhou - EVP
Ge Li - NEC
Edward Hu - NED
Yibing Wu - NED
Yanling Cao - NED
Shaohua Lu-Wong - CFO
Jing Li - SVP
Jian Dong - SVP
Angus Scott Turner - VPR
Chiang Syin - SVP
Yue Huang - SEC
Ying Man Sham - SEC
Jijie Gu - EVP
Kenneth Walton Hitchner - NID
Who are the major shareholders of WuXi Biologics (Cayman) Inc?

Here are the top five shareholders of WuXi Biologics (Cayman) Inc based on the size of their shareholding:

WuXi Biologics Holdings Limited Corporation
Percentage owned: 23.31% (317.1m shares)
Capital Research Global Investors Investment Advisor
Percentage owned: 6.53% (88.8m shares)
American Funds EuroPacific Growth Fund Mutual Fund
Percentage owned: 4.98% (67.7m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 2.34% (31.8m shares)
JP Morgan Asset Management Investment Advisor
Percentage owned: 2.11% (28.7m shares)
Similar to 2269
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.